We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
-4.81%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
-$87.1M
Cap. Flow
-$47.5M
Cap. Flow %
-16.99%
Top 10 Hldgs %
59.73%
Holding
57
New
12
Increased
11
Reduced
3
Closed
20

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$19.9M
2
MRUS
Merus
MRUS
+$18.4M
3
NUVL
Nuvalent
NUVL
+$17.6M
4
SLNO
Soleno Therapeutics
SLNO
+$11.4M
5
RVMD icon
Revolution Medicines
RVMD
+$9.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$82M
2
NVO
Novo Nordisk
NVO
+$58.6M
3
VKTX icon
Viking Therapeutics
VKTX
+$25.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.79M
5
AXSM icon
Axsome Therapeutics
AXSM
+$7.89M

Sector Composition

Rank Sector Weight
1 Healthcare 88.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
51
Madrigal Pharmaceuticals
MDGL
$11.7B
– –
-1,557
Closed -$330K
SLN
52
Silence Therapeutics
SLN
$523M
– –
-52,476
Closed -$954K
SLRN
53
DELISTED
ACELYRIN
SLRN
– –
-93,114
Closed -$459K
SMMT icon
54
Summit Therapeutics
SMMT
$10.8B
– –
-14,512
Closed -$318K
SNDX icon
55
Syndax Pharmaceuticals
SNDX
$1.73B
– –
-48,263
Closed -$929K
VRTX icon
56
Vertex Pharmaceuticals
VRTX
$122B
– –
-18,900
Closed -$8.79M
QTTB icon
57
Q32 Bio
QTTB
$478M
– –
-4,705
Closed -$210K
1 2
3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $498M AUM 20.41% 1-Year Est. Return

Artia Global Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Artia Global Partners held 57 positions worth $280M, down 24% from $367M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artia Global Partners withdrew a net $47.5M in Q4 2024, closing 20 positions and reducing 3 holdings. Its most notable exit was Eli Lilly, an estimated $82M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 96% a quarter earlier.

Against the trend, Artia Global Partners opened a new position in Arcellx worth $17.6M.

  • Artia Global Partners's largest Q4 2024 buy was Arcellx: 229,785 shares worth $17.6M.
  • Artia Global Partners added most to Merus in Q4 2024, an estimated $18.4M increase.
  • Artia Global Partners's biggest Q4 2024 reduction was Novo Nordisk, cutting an estimated $58.6M.
  • Artia Global Partners fully exited Eli Lilly in Q4 2024, selling an estimated $82M.
  • Artia Global Partners's ten largest holdings make up 60% of its $280M portfolio in Q4 2024.
  • Artia Global Partners opened 12 new positions and closed 20 in Q4 2024.
  • Artia Global Partners's portfolio value fell 24% quarter-over-quarter to $280M.

Based on Artia Global Partners's 13F filing for Q4 2024, filed 14 Feb 2025.